
|Videos|October 18, 2017
Dr. Shah Discusses Autologous Transplant in MCL
Author(s)Bijal D. Shah, MD
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).
Advertisement
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).
Not all patients with MCL in first remission should receive ASCT, says Shah. The main alternative would be rituximab (Rituxan) maintenance therapy, but there is not yet enough information on duration of treatment with this approach.
Shah says, at this point, it is up to the patient to either undergo transplant or rituximab maintenance.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































